465 related articles for article (PubMed ID: 18805108)
1. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
[TBL] [Abstract][Full Text] [Related]
2. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study.
Klein AL; Jasper SE; Katz WE; Malouf JF; Pape LA; Stoddard MF; Apperson-Hansen C; Lieber EA;
Eur Heart J; 2006 Dec; 27(23):2858-65. PubMed ID: 17098762
[TBL] [Abstract][Full Text] [Related]
3. Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).
Zhao L; Zhang Z; Kolm P; Jasper S; Lewis C; Klein A; Weintraub W;
Am J Cardiol; 2008 Feb; 101(3):338-42. PubMed ID: 18237596
[TBL] [Abstract][Full Text] [Related]
4. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.
Elliott DJ; Zhao L; Jasper SE; Lieber EA; Klein AL; Weintraub WS
Am Heart J; 2008 Aug; 156(2):374.e1-6. PubMed ID: 18657673
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
6. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
7. [Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol].
Antonielli E; Pizzuti A; Gandolfo N; Sclavo M; Tanga M; Riva G; Leonardi G; Bassignana A; Di Leo M
G Ital Cardiol; 1997 Aug; 27(8):803-10. PubMed ID: 9312508
[TBL] [Abstract][Full Text] [Related]
8. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study.
Murray RD; Shah A; Jasper SE; Goodman A; Deitcher SR; Katz WE; Malouf JF; Stoddard MF; Grimm RA; Klein AL;
Am Heart J; 2000 Jun; 139(6):E1-7. PubMed ID: 10827367
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial.
Klein AL; Grimm RA; Jasper SE; Murray RD; Apperson-Hansen C; Lieber EA; Black IW; Davidoff R; Erbel R; Halperin JL; Orsinelli DA; Porter TR; Stoddard MF;
Am Heart J; 2006 Feb; 151(2):380-9. PubMed ID: 16442904
[TBL] [Abstract][Full Text] [Related]
10. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
11. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
[TBL] [Abstract][Full Text] [Related]
12. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.
Garcés EO; Victorino JA; Thomé FS; Röhsig LM; Dornelles E; Louzada M; Stifft J; de Holanda F; Veronese FV
Ren Fail; 2010 Jan; 32(3):320-7. PubMed ID: 20370447
[TBL] [Abstract][Full Text] [Related]
14. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
15. SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study.
Cohen A; Stellbrink C; Le Heuzey JY; Faber T; Aliot E; Banik N; Kropff S; Omran H;
Arch Cardiovasc Dis; 2015 Feb; 108(2):122-31. PubMed ID: 25684570
[TBL] [Abstract][Full Text] [Related]
16. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
Drouet L; Bal dit Sollier C; Martin J
Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
[TBL] [Abstract][Full Text] [Related]
17. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
[TBL] [Abstract][Full Text] [Related]
18. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
[TBL] [Abstract][Full Text] [Related]
19. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
Schädlich PK; Schmidt-Lucke C; Huppertz E; Lehmacher W; Nixdorff U; Stellbrink C; Brecht JG
Am J Cardiovasc Drugs; 2007; 7(3):199-217. PubMed ID: 17610347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]